CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ...

Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make ...

Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...

INSIGHT-003, a multi-centre study led by the Frankfurt Institute of Clinical Cancer Research IKF, is nearing completion of ...

I-Mab, a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies ...

With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part ...

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adultsCosibelimab PDUFA goal date of December 28 for ...

Key data: These results compare favourably to the 22.0-month median OS, 9.0-month median PFS, and 24-month OS rate of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy in ...

Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is 32.9 ...